Huge thanks to European Government backed Sofia Angels Ventures for their investment in Digistain.
The €13M venture fund supported by European Investment Fund (EIF) for angel and private co-investment, Sofia Angels Ventures announced that it had made its fourth investment, backing UK-based medtech startup Digistain. The funding will aim to help the company receive FDA approval, as well as complete new clinical trials, further build up the team, and start commercial activities.
Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024. The first abstract showcased head-to-head data from Charing
We’re excited to announce that Digistain® has partnered Deloitte to drive adoption across Europe! This collaboration marks a significant step toward making breast cancer risk
We’re thrilled to announce that Digistain® is now available to over 60% of UK private patients, with reimbursement available though Bupa, WPA Health Insurance &
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.